Contact Us | Print Page | Sign In | Register
News & Press
Filter news by category:

Read about recent events, essential information and the latest community news.

Displaying page 1 of 12
1  |  2  |  3  |  4  |  5  |  6  >   >>   >| 

CMSC Industry News for MS (INforMS)
Friday, September 11, 2020
CMSC INforMS: New Data Further Reinforce Genentech’s Ocrevus (ocrelizumab) as Effective Treatment »
New Data Further Reinforce Genentech’s Ocrevus (ocrelizumab) as a Highly Effective Treatment for People With Multiple Scle...
Monday, August 24, 2020
FDA Approves Genentech’s Enspryng for Neuromyelitis Optica Spectrum Disorder First and only FDA-approved subcutaneous...
Wednesday, August 19, 2020   (0 Comments - view/add)
CMSC INforMS: Mylan Brings Critical Access to the MS Community »
Mylan Brings Critical Access to the Multiple Sclerosis Community by Launching a More Affordable Treatment Option Through a...
Saturday, July 11, 2020   (0 Comments - view/add)
CMSC INforMS: A Letter from Lemtrada Regarding its Home Phlebotomy Partner, EMSI »
Good Day Lemtrada Patient – On July 3, 2020 Sanofi Genzyme was notified that our Lemtrada Home Phlebotomy Partner, E...
Thursday, June 11, 2020
CMSC INforMS: Inebilizumab Approved for Treatment of Neuromyelitis Optica Spectrum Disorder »
The treatment, marketed as Uplizna, is only the second approved therapy for NMOSD.  The US FDA has approved ine...
Monday, June 1, 2020
CMSC INforMS: Press Release - ZEPOSIA launch press release »
Bristol Myers Squibb Announces Commercial Launch and Availability of ZEPOSIA ® (ozanimod), a New Oral Treatment for Relap...
Wednesday, May 27, 2020
CMSC INforMS: Press Release - Rebif® U.S. Label Includes Pregnancy Outcomes & Lactation Information »
- Label update is based on data from a large register-based study, as well as other published studies over several decades...
Monday, April 27, 2020
CMSC INforMS: Press Release - New 6-Year Data for Genentech’s Ocrevus (ocrelizumab) Findings »
New 6-Year Data for Genentech’s Ocrevus (ocrelizumab) Show Earlier Treatment Initiation Nearly Halves Risk of Needing Walk...
Tuesday, March 31, 2020
CMSC INforMS: Avonex and Plegridy Label Updates »
The Plegridy (peginterferon beta-1a) Prescribing Information and the Avonex (interferon beta-1a) Prescribing Information w...
Friday, March 27, 2020
CMSC INforMS: CMSC Annual Meeting, May 27-30, 2020 in Orlando, FL Announces Cancellation »
Leading Educational Non-Profit for Multiple Sclerosis Healthcare Professionals to Provide Virtual and Web-Based Accredited...
Thursday, March 26, 2020
CMSC INforMS: FDA Approves Zeposia (Ozanimod), Oral Therapy for All with Relapsing MS »
The U.S. Food and Drug Administration (FDA) has approved Zeposia ( ozanimod ) oral capsules to treat adults with relap...
Tuesday, March 10, 2020
CMSC INforMS: MedDay Report Top-Line Data from trial “SPI2” for Treatment of Progressive Forms of MS »
Paris, France, March 10, 2020 – MedDay Pharmaceuticals announced today that the second pivotal Phase III trial (SPI2) of...
Monday, February 3, 2020   (0 Comments - view/add)
CMSC INforMS: Participate in a study evaluating a potential treatment options for RRMS Relapses »
The OPTIONS Study is looking at how well a study drug works for adults with relapsing-remitting multiple sclerosis (RRMS)...
Tuesday, January 21, 2020
CMSC INforMS: Brain Activity Patterns Linked with Improved Learning and Memory in multiple sclerosis »
A recent article by Kessler Foundation researchers demonstrated g people with multiple sclerosis (MS). The article, "Brain...
Saturday, January 18, 2020
CMSC INforMS: Robotic 'Trousers' Could Help Thousands of MS Sufferers Stand and Walk Again »
Robotic ‘trousers’ could help thousands of people left unable to stand or walk due to multiple sclerosis find their feet a...
Friday, January 17, 2020
CMSC INforMS: CMSC Announces 4 Winners of Pilot Research Awards for 2019 »
The Consortium of Multiple Sclerosis Centers (CMSC) named four scientists the winners of its Pilot Research Award for 20...
Thursday, January 2, 2020
CMSC INforMS: Use of DMTs Changing ‘Natural History’ of Relapsing MS, Study Says »
People with relapsing multiple sclerosis (MS) have a better prognosis and a slower progression to disability since the i...
Thursday, December 5, 2019
CMSC INforMS: FDA Approves First Generics for Common Multiple Sclerosis Drug »
The FDA has approved 3 applications for generics of fingolimod (Gilenya, Novartis). These are the first generics of the dr...
Sunday, December 1, 2019
CMSC INforMS: PRESS RELEASE - Results for Genentech’s Satralizumab in Neuromyelitis Optica Spectrum »
Positive Phase III Results for Genentech’s Satralizumab in Neuromyelitis Optica Spectrum Disorder Published in the New Eng...
Tuesday, November 26, 2019
CMSC INforMS: PRESS RELEASE - NeurologyLive™ Adds CMSC to Its Strategic Alliance Partnership Program »
CRANBURY, N.J.--( BUSINESS WIRE )-- NeurologyLive™ , a multimedia platform dedicated to providing health care professional...
Monday, November 11, 2019   (0 Comments - view/add)
In Memoriam: Alan Mandel »
Our dear friend and colleague Alan Mandel passed away early Monday morning, November 4, 2019. He fought hard in his battle...
Monday, October 7, 2019
CMSC INforMS: Kessler scientists receive grant to study exercise benefits in multiple sclerosis »
Consortium of Multiple Sclerosis Centers awards grant to Drs. John DeLuca and Helen Genova to study the effects of differe...
Tuesday, September 17, 2019
CMSC INforMS: EMD Serono Initiates Pivotal Phase III Program for Investigational Evobrutinib in RMS »
- EVOLUTION RMS 1 and 2 pivotal Phase III trials will investigate the efficacy and safety of evobrutinib in relapsing mult...
Thursday, September 12, 2019
CMSC INforMS: Genentech Presents New Six-Year Ocrevus (Ocrelizumab) Data »
Genentech Presents New Six-Year Ocrevus (Ocrelizumab) Data Which Showed That Earlier Initiation and Continuation of Treatm...
Wednesday, September 11, 2019
CMSC INforMS: Genentech’s Satralizumab Significantly Reduced Relapse Risk »
Genentech’s Satralizumab Significantly Reduced Relapse Risk in Second Positive Phase III Study for Neuromyelitis Optica Sp...
Tuesday, September 10, 2019
CMSC INforMS: Janet Brown Obituary »
  Janet Brown ( December 30, 1964 - September 08, 2019 ) Ms. Janet Marie Brown, MSN, FNP-BC, MSCN, age 5...
Monday, September 9, 2019
CMSC INforMS: Genentech Presents New Ocrevus (Ocrelizumab) Biomarker Data »
Genentech Presents New Ocrevus (Ocrelizumab) Biomarker Data That Increase Understanding of Disease Progression in Multiple...
Saturday, September 7, 2019
CMSC INforMS: Dr Daniel Kantor Highlights MS Treatments and What Is in the Pipeline »
The field of treatments for multiple sclerosis (MS) has grown quickly in the last 30 years, but the next new class of ther...
Wednesday, September 4, 2019
CMSC INforMS: MS Relationships Improved by Togetherness and Communication, Study Suggests »
Relationships between multiple sclerosis patients and their intimate partners were enhanced when the couple worked toget...
Tuesday, September 3, 2019
CMSC INforMS: Press Release - Genetech to present Piviotal Data at ECTRIMS »
Genentech to Present Pivotal Data for Satralizumab in Neuromyelitis Optica Spectrum Disorder and Six-Year Ocrevus (Ocreliz...
Thursday, August 29, 2019
CMSC INforMS: Social cognition, mood and fatigue in multiple sclerosis »
Study by MS research team links deficits in social cognition with fatigue, depressive symptomatology, and anxiety Da...
Saturday, August 24, 2019
CMSC INforMS: The Genetic and Environmental Factors That Can Cause Multiple Sclerosis »
Researchers say genetic makeup is a factor, but so are smoking, obesity, vitamin D, and viral infections. A combinatio...
Wednesday, August 7, 2019
CMSC INforMS: Rutgers Health Leading Program to Support MS Children »
Rutgers Health is leading the Pediatric Multiple Sclerosis and Demyelinating Diseases Program , the only program in the...
Thursday, July 18, 2019
CMSC INforMS: Dr. Anne Cross Discusses Strides In Multiple Sclerosis Research, Recent Award »
Years ago, when many multiple sclerosis researchers believed that a type of immune cell known as a T-cell was the cause of...
Tuesday, July 16, 2019
CMSC INforMS: EMD Serono’s Embracing Carers Launches ‘Time Counts’ to Raise 1M Minutes of Support »
●   ‘Time Counts’ launches as a social media-led video series asking individuals to collectively give 1 million mi...

Displaying page 1 of 12
1  |  2  |  3  |  4  |  5  |  6  >   >>   >| 

The Consortium of Multiple Sclerosis Centers

3 University Plaza Drive, Suite 116 Hackensack, NJ 07601

Tel: 201.487.1050 | Fax: 862.772.7275